Filing Flows › ASP Isotopes (ASPI) › Q2 2026 › vs Q2 2025
ASP Isotopes (ASPI) Q2 2026 vs Q2 2025 (year over year)
ASP Isotopes's revenue rose $3.9M (+328%) from $1.2M in Q2 2025 to $5.1M in Q2 2026. The biggest changes: Product +$3.3M (+278%); Collaboration Revenue +$600K (—).
ASP Isotopes, Q2 2026: revenue $5.1M (+328% year over year), operating margin -667.5%, net loss $34.0M, operating cash flow −$23.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Product | $4.5M | $1.2M | $3.3M | +278% |
| Collaboration Revenue | $600K | $0 | $600K | — |
| Revenue | $5.1M | $1.2M | $3.9M | +328% |
| Other income, net | $105K | −$63.1M | $63.2M | — |
| Income tax benefit | $97K | −$95K | $192K | — |
| Net loss | $34.0M | $75.2M | −$41.2M | -55% |
| Costs & expenses | $39.3M | $76.4M | −$37.0M | -49% |
| Operating costs | $39.3M | $13.2M | $26.2M | +199% |
| Cost of revenue | $3.6M | $626K | $3.0M | +482% |
| Research & development | $6.8M | $880K | $5.9M | +675% |
| General & admin | $28.9M | $11.7M | $17.2M | +147% |
| Operating cash sources | $34.0M | $75.2M | −$41.2M | -55% |
| Depreciation & amortization | $1.2M | $530K | $672K | +127% |
| Share-based compensation | $4.5M | $4.4M | $113K | +3% |
| Working capital & other | $4.9M | $62.3M | −$57.4M | -92% |
| Cash used in operations | $23.3M | $7.9M | $15.4M | +195% |
| Net loss absorbed | $34.0M | $75.2M | −$41.2M | -55% |
Questions
How much did ASP Isotopes's revenue grow year over year in Q2 2026?
ASP Isotopes's revenue rose $3.9M (+328%) from $1.2M in Q2 2025 to $5.1M in Q2 2026.
What drove ASP Isotopes's revenue change in Q2 2026?
Product +$3.3M (+278%); Collaboration Revenue +$600K (—).